Shantharam Harish 4

What Happened Shantharam Harish, Chief Financial Officer of ALX Oncology Holdings, received a grant/award of 303,000 derivative shares on January 26, 2026. The filing reports an acquisition at $0.00 (no cash paid at grant). This is an executive equity award (not an open‑market purchase or sale), so it represents compensation rather than an immediate buy/sell signal.

Key Details

• Transaction date: 2026-01-26; Form 4 filed: 2026-01-28 (appears timely).
• Instrument: Derivative award (code A — grant/award); reported price $0.00.
• Amount granted: 303,000 shares (reported as derivative).
• Shares owned after transaction: not specified in the provided excerpt.
• Footnote: F1 — the shares are subject to an option that vests in 48 equal monthly installments beginning February 26, 2026.
• No mention in the excerpt of 10b5-1, tax withholding disposition, or a late filing flag.

Context This filing documents an option-style award to the CFO that vests monthly over four years, meaning the shares are not immediately transferable or saleable. Awards like this are a common form of executive compensation and do not by themselves indicate the insider is buying or selling stock in the market.